Search Results
Invex Therapeutics rolls-out Evolve phase III trial for drug Presendin in IIH patients
Invex Therapeutics (ASX:IXC) Approval to commence clinical trial
Invex Therapeutics’ new partnership de-risks Presendin development
Invex Therapeutics Presentation - 2021 NWR Virtual Investor Conference
Invex Therapeutics Q3 FY22 Investor Presentation
ASX Small & Mid Cap Conference: Invex Therapeutics
IIH:WT - Weight Trial
New Trial - Shunts versus Stents
Invex Therapeutics Q2 FY23 Conference Call
Invex Therapeutics (ASX:IXC): Emerging ASX Gems presentation
Idiopathic Intracranial Hypertension Journey
Living with IIH
